A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
2014 · Nature Communications · 113 citations
https://doi.org/10.1038/ncomms4608
E
Eva Martinez‐Balibrea
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
83
Papers
2.7K
Citations
24
h-index
31
i10-index
Eva Martinez‐Balibrea is an academic researcher from Institut Català d'Oncologia. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Cancer Treatment and Pharmacology & Cancer Genomics and Diagnostics. The author has an h-index of 24, co-authored 71 publications.
ORCID: 0000-0002-4501-7100Papers by this author
worksUGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
2010 · British Journal of Cancer · 88 citations
https://doi.org/10.1038/sj.bjc.6605776
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
2022 · The Breast · 11 citations
https://doi.org/10.1016/j.breast.2022.01.007
Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment
2024 · Biomedicine & Pharmacotherapy · 5 citations
https://doi.org/10.1016/j.biopha.2024.116857
Correction: Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
2016 · Nature Communications · 4 citations
https://doi.org/10.1038/ncomms13467
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat